Home

How is Hunter syndrome treated

Sichern Sie sich exklusive Angebote der Marke Hunter bei STYLEBOP. Mode von Hunter direkt von den internationalen Runways Jetzt die Top-Marke Hunter im Breuninger E-Shop entdecken! Entdecken Sie jetzt das angesagte Sortiment von Hunter im Breuninger E-Shop Treatment for skeletal and connective tissue problems Because most children with Hunter syndrome don't heal well and often have complications after surgery, options are limited for addressing skeletal and connective tissue complications. For example, surgery to stabilize the spine using internal hardware is difficult when bones are fragile Treatment for Hunter syndrome depends on the symptoms. A team approach, with specialists in different areas of expertise, could help manage the potential problems associated with the condition and give patients the best possible care. The goal of treatment is to slow the progression of the disease and improve quality of life Hunter syndrome is far more common in boys. The condition is one type of a group of inherited metabolic disorders called mucopolysaccharidoses (MPSs). Hunter syndrome is also known as MPS II. There's no cure for Hunter syndrome

Designermode von Hunter - Hunter Kollektio

Currently, there is no cure for Hunter syndrome. Medical care is directed towards relieving the symptoms of MPS II. Treatment with Elaprase (idursulfase) replaces I2S in the body and helps reduce symptoms and pain. The respiratory tract may become obstructed, so good respiratory care and monitoring are important No cure exists for Hunter Syndrome. Currently, the only FDA-approved treatment on the market, enzyme replacement therapy (ERT), is able to stabilize many of the physical symptoms of Hunter Syndrome Background: Bow hunter's syndrome is a rare vascular phenomenon characterized by insufficiency of the posterior cerebral circulation induced by rotation of the head within normal physiologic range. The neurosurgical literature on evidence-based diagnosis and management of the disease is scarce, and reports are largely limited to case studies Bone Marrow Transplantation: This method of treatment can be used for mild forms of Hunter Syndrome and has shown to be effective. This treatment controls difficulty breathing, facilitates better mobility, and also improves cardiac, liver, and spleen function. It also helps with improvement of mental function of the child Treatment for Hunter syndrome is mainly confined to reducing symptoms or slowing symptom development with idursulfase (Elaprase). There is no cure for Hunter syndrome. Complications of Hunter syndrome can involve all of the organ systems, including respiratory, skeletal, connective tissue, cardiac, and brain (neurologic)

When your son has Hunter syndrome, there are things you can do to help them play, have friends, and do some of the things that other kids do, even though they may look different from their pals... Some of these treatments include: Bone marrow transplantation - In milder cases of Hunter syndrome, bone marrow transplantation may be performed to provide a new source of the deficient.. Hunter syndrome treatment The U.S. Food and Drug Administration has approved the first treatment for Hunter syndrome. The medicine, called idursulfase (Elaprase), is given through a vein (intravenously). Talk to your doctor for more information The complexity and challenges of cervical neck instability treatment is fully displayed in the controversies and confusions surrounding the diagnosis of vertebrobasilar insufficiency, also called vertebrobasilar artery insufficiency or Bow Hunter Syndrome. As a patient diagnosed with one of these diagnostic tags, you probably know first hand that your journey of treatment has taken many turns Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a rare genetic disorder in which large sugar molecules called glycosaminoglycans (or GAGs or mucopolysaccharides) build up in body tissues. It is a form of lysosomal storage disease.Hunter syndrome is caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S). The lack of this enzyme causes heparan sulfate and.

Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a member of a group of inherited metabolic disorders collectively termed mucopolysaccharidoses (MPSs). The MPSs are caused by a deficiency of lysosomal enzymes required for the degradation of mucopolysaccharides or glycosaminoglycans (GAGs) MPSII or Hunter Syndrome is a lysosomal storage disease caused by a deficiency in the enzyme iduronate 2-sulfatase. Research and studies have developed a IDS2 gene that is attached to a vector and is being injected into mice models in preparation for a clinical trial in humans MPS II is a mucopolysaccharide disease known as Hunter syndrome. It takes its name from Charles Hunter, the professor of medicine in Manitoba, Canada, who first described two brothers with the disease in 1917. MPS II has a wide range of symptoms that vary in severity and can be managed and treated with enzyme replacement therapies In Hunter syndrome, GAG build up in cells interferes with the way certain cells and organs in the body function and leads to a number of serious symptoms. Physical manifestations for some people with Hunter syndrome include distinct facial features, a large head, an enlarged abdomen and joint problems. People with Hunter syndrome may also.

Meet the snake boy who has shed his skin every 41 daysAIM ImmunoTech Announces IRB Approval to Enroll COVID-19

Hunter - Sortiment von Hunte

  1. How does the treatment work? Hunter syndrome results from a mutation in a gene for an enzyme that cells need to break down certain sugars. When the enzyme is defective or missing, the sugars build.
  2. The Hunter Syndrome Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive.
  3. antly in males. Iduronate 2-sulfatase (IDS) is responsible for the breakdown of large sugar molecules called glycosa
  4. istered intrathecally for the treatment of pediatric patients with Hunter syndrome and cognitive impairment. In clinical trials, SHP609 is ad
  5. The current treatment for Hunter syndrome, weekly spinal infusions, costs about $500,000 a year. Providing gene therapy for nine children enrolled in a trial saves money

Hunter syndrome - Diagnosis and treatment - Mayo Clini

  1. ation is an ideal blend of subjective and quantitative data featuring key market improvements, challenges that industry and rivalry is looking alongside whole investigation and new open door accessible and may slant in.
  2. Hunter Syndrome Detailed Epidemiology Segmentation. The total diagnosed prevalent population of Hunter Syndrome in the 7 major markets was found to be 1,145 in 2017. In case of Hunter Syndrome patients in the United States, the diagnosed prevalent cases were found to be 503 in 2017
  3. Keywords: Mucopolysaccharidosis type II, Hunter syndrome, Enzyme replacement therapy, Idursulfase, Treatment recommendations Introduction First described by Major Charles Hunter in 1917 [ 15 ], mucopolysaccharidosis type II (MPS II or Hunter syndrome; OMIM +309900) is an X-linked recessive disease caused by deficiency of the lysosomal enzyme.
  4. Mucopolysaccharidosis type II (MPSII), or Hunter syndrome, is an X-linked, progressive, multisystem disorder caused by deficiency of the lysosomal enzyme iduronate-2-sulfatase, encoded by the IDS.
  5. Hunter syndrome is an X-linked disorder, meaning that it is transmitted on the X chromosome from a mother to her children. Because of how Hunter syndrome is inherited, the condition is more common in men—although women, in rare cases, can inherit the condition too. Hunter syndrome can occur in any ethnic group
  6. Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. It is a progressively debilitating disorder; however, the rate of progression varies among affected individuals. At birth, individuals with MPS II do not display any features.
  7. Hunter syndrome is one of a number of lysosomal storage diseases (LSDs). It is estimated that the condition is present in 1 in 162 000 live births. Hunter syndrome can affect any part of the body and causes a number of signs and symptoms. In the majority of people with Hunter syndrome, the signs and symptoms present between the ages of 2 and 4.

Giugliani R, Villarreal MLS, Valdez CAA, et al. Guidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America. Genetics and Molecular Biology . 2014;37(2):315-329. A definitive diagnosis of Hunter syndrome is made by measuring iduronate-2-sulfatase (I2S) activity. This can be done by taking blood and testing the I2S activity in serum or white blood cells, or by taking a skin biopsy and testing the I2S activity in skin fibroblasts

Hunter Syndrome: Causes, Symptoms, Diagnosis, Treatment

The gene responsible for MPS II is known as the iduronate 2-sulfatase (IDS) gene. In many individuals with MPS II, the condition is caused be relatively small changes (e.g., certain missense or nonsense mutations) in the IDS gene, or deletion or insertion of genetic material (e.g., single-base deletions or insertions) that affects gene function The Hunter syndrome treatment market report provides a detailed analysis of the market dynamics and focuses on key aspects such as prevalence of Hunter syndrome, by key regions, 2018, pipeline analysis, key industry developments, regulatory scenario by key regions, overview of emerging treatments for Hunter syndrome, and, reimbursement scenario.

Hunter syndrome - Symptoms and causes - Mayo Clini

  1. The global Hunter Syndrome Treatment Market is predicted to reach USD 1,118.4 million by 2026, exhibiting a CAGR of 6.0% during the forecast period. The increasing RD investments by key players for the development of novel therapies to treat rare diseases in patients will be critical factor in boosting the Hunter syndrome treatment market growth during the forecast period
  2. Global demand for hunter syndrome treatment market was valued at approximately USD 927.9 million in 2019, and is expected to generate revenue of around USD 1,601.6 million by end of 2026, growing at a CAGR of around 8.2% between 2020 and 2026
  3. The intensity of treatment depends on the severity of the syndrome.19 Mild cases generally resolve within 24 to 72 hours with conservative therapy and removal of the causative drugs. Most patients.
  4. Bow Hunter Syndrome Treated Via an Anterior Approach and Selective Decompression Only Volume 9- Issue 5 Jung Hoon Kang 1, Soo Bin Im* 1, Je Hoon Jeong 1, Dong Seong Shin 1, Sang Mi Yang 1 and Jong Hyeon Mun 2. 1 Depertment of Neurosurgery, Soonchunhyang University College of Medicine, Republic of korea
  5. istered in Conjunction with Elaprase® in Patients with Hunter Syndrome and Cognitive Impairment
  6. Hunter Syndrome Treatment Market - Dynamics. As Hunter syndrome has no permanent cure, the treatment mainly focuses on management of indications, signs, and difficulties associated with the disease advancement. Increasing number of population suffering from hunter syndrome has boosted the market growth for Hunter syndrome treatments
  7. Those with Madeux's condition, Hunter syndrome, lack a gene that makes an enzyme that breaks down certain carbohydrates. These build up in cells and cause havoc throughout the body

The hunter syndrome treatment market is segmented on the basis of treatment, complications, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets With new drugs arriving soon, the global Hunter Syndrome treatment market is bound to grow in the coming years. Hunters Syndrome is a genetic disorder, mostly found in males. Men possess an X and a Y chromosome, and this diseases occurs due to a recessive X chromosome. This leads to deficiency of an enzyme called iduronate-2-sulfatase, causing. Hunter Syndrome Treatment Market. The scope of this report covers the different types of Hunter Syndrome Treatment along with emerging therapies for the treatment of Hunter Syndrome Treatment. The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 fo Background: Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is a rare, X-linked disorder caused by deficient activity of the enzyme iduronate-2-sulfatase (I2S). Treatment is available in the form of enzyme replacement therapy (ERT) with recombinant I2S. Clinical outcomes following ≥3 years of ERT with idursulfase were investigated in a broad population of patients with MPS II.

Hunter Syndrome is an X-linked lysosomal storage disorder due to the deficit of iduronate 2-sulfatase, an enzyme catalysing the degradation of the glycosaminoglycans (GAG) dermatan- and heparan-sulfate. Treatment of the disease is mainly performed by Enzyme Replacement Therapy (ERT) with idursulfase, in use since 2006. Clinical efficacy of ERT has been monitored mainly by the Hunter Outcome. 6.11.4 Info Graphic Analysis. The Global Hunter Syndrome Treatment Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process

Gene editing, in a patient's body, attempted for 1st time

Hunter Syndrome (MPS II) Children's Hospital Pittsburg

  1. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). Cochrane Database Syst Rev 2016; 2:CD008185. Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008; 167:267
  2. Hunter syndrome or Mucopolysaccharidosis type 2 is an inherited genetic disorder caused by malfunctioning or missing enzyme. Hunter syndrome affects several parts of the body and shows symptoms.
  3. The global Hunter syndrome treatment market size was valued at USD 864.9 million in 2018. Introduction of novel therapies, robust product pipeline, increasing awareness regarding Hunter syndrome, and rising government initiatives is fueling the market growt
  4. The high cost involved in the treatment of hunter syndrome is restraining the growth of the global hunter syndrome treatment market. For instance, the current treatment cost for hunter syndrome costs an amount of $250,000 to $500,000 per year per patient
  5. The Hunter syndrome treatment market size is predicted to reach USD 1,118.4 million by 2026. The rising need for better treatment will spur opportunities for the Hunter syndrome treatment market in the foreseeable future. Also, the growing demand for advanced therapeutics to treat Hunter syndrome will accelerate the global Hunter syndrome treatment market trends during the forecast period.
  6. Two brothers with Hunter Syndrome move Delhi High Court seeking free treatment. The annual cost of treatment for Hunter Syndrome in India is estimated to cost between 80 lakh to one crore for one.
Cases discussions about neuroradiology and neurosurgery

Although there are some signs that the treatment reduced levels of a biochemical marker used to assess the severity of Hunter syndrome, it is too soon to know whether the therapy worked The global Hunter Syndrome Treatment market size is expected to grow at a CAGR of 4.1% for the next five years. Market segmentation Hunter Syndrome Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application

Mucopolysaccharidoses Fact Sheet National Institute of

Hunter Syndrome Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hunter Syndrome Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type. The global Hunter syndrome treatment market size is expected to reach a value of USD 1.52 billion by 2026, expanding at a CAGR of 7.1%, according to a new report by Grand View Research, Inc. High unmet needs, robust pipeline, increasing awareness about this rare disease and growing R&D activities for the development of novel therapies are expected to drive market growth over the forecast perio

In April 2020, Clinigen K.K. applied for the approval of Hunterase Intracerebroventricular (ICV) for the treatment of Hunter syndrome to Japan's Medical and Medical Device Organization A Study of Potential Treatment-Responsive Biomarkers in Hunter Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

Hunter Syndrome Treatment Market |2021 Analysis, Key Opportunities Major Players, Impact of COVID-19 and Size, Growth, Share, Regional Analysis With Global Industry Forecast To 2027, The global. The global Hunter syndrome treatment market size is predicted to reach USD 1,118.4 million by 2026, exhibiting a CAGR of 6.0% during the forecast period. The increasing R&D investments by. Hunter syndrome. Hunter syndrome is mucopolysaccharidosis type 2. Hunter syndrome patients present with similar features as in Hurler syndrome, but patients with Hunter syndrome present in later onset with a slower clinical course and absence of corneal manifestations. Sly syndrome. Sly syndrome is mucopolysaccharidosis type 6 Investors tracking Denali Therapeutics' Hunter syndrome therapy were left unimpressed after results from an exploratory endpoint showed ongoing brain cell death even with treatment. Shares of. RGX-121 is a product candidate for the treatment of Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome. RGX-121 is designed to use the AAV9 vector to deliver the human iduronate-2-sulfatase gene (IDS) which encodes the iduronate-2-sulfatase (I2S) enzyme to the central nervous system (CNS)

Management of severe TURP syndromeWeek 5 Lysosomes, Peroxisomes, and Mitochondria - Clinical

What Are The Treatment Options For Hunter Syndrome

The mild, or attenuated form of MPS I is also known as Scheie syndrome or MPS I S: Children born with this form have normal intelligence and may live to adulthood.; The severe form of MPS I is known as Hurler syndrome or MPS I H: Children affected with the severe form may have mental retardation, short stature, stiff joints, speech and hearing impairment, heart disease, and a shortened lifespan Los Angeles, USA, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Hunter Syndrome Clinical Trial Analysis of 10+ Companies Active in the Treatment Landscape The Key companies developing drugs are Denali. The more severe form of Hunter syndrome usually has a disease onset between ages 2 and 4 years. Mental impairment and developmental decline is usually noticed at 18-24 months with progressive loss of motor skills. Death from upper airway obstruction or heart failure occurs by age 15. TREATMEN

About Miniature Schnauzers

Hunter Syndrome Symptoms and Treatmen

Investors tracking Denali Therapeutics' Hunter syndrome therapy were left unimpressed after results from an exploratory endpoint showed ongoing brain cell death even with treatment. Shares of the South San Francisco, California-based biotech fell 13% to $55.34 as the markets opened Monday. Looking at the data drop, Denali got the safety data it was looking for, plus The current options of conservative treatment, surgical fusion, or vertebral artery decompression must be weighed against patients' medical condition and personal desires. This article presents two case illustrations and reviews the natural history, diagnosis, and treatment of bow hunter's stroke. Illustrative Cases. Case 1. Figure 1

Hunter Syndrome - Project Aliv

Market Study Report presents an extensive report on Hunter Syndrome Treatment market that offers qualitative information about prevailing trends and a detailed analysis of the growth trajectory of this industry. It also includes a study of the historical data and detailed statistics that will help determine the future scope of the industry in terms of commercialization opportunities Describe current and investigative options available for management of Hunter syndrome, and design a medical plan to treat a patient with Hunter syndrome. Describe present barriers to care in the treatment of patients with Hunter syndrome. Describe the clinical outcomes associated with Hunter syndrome treatment

Diagnosis and management of bow hunter's syndrome: 15-year

The management of Hunter syndrome consists of supportive care and treatment of complications. Enzyme replacement therapy with recombinant IDS (idursulfase) is now available; it has been demonstrated to be able to improve joint mobility, general endurance (measured by the 6-min walk test), and lung function, but does not have any effect on the. Enzyme replacement treatment is the most common procedure used to treat Hunter's Syndrome. There is a relatively new medication used to treat Hunter's Syndrome which is called Elaprase. This medication infuses the enzyme into a child with Hunter's Syndrome through the veins. This treatment helps to break down the Mucopolysaccharides that.

Hunter Syndrome: Treatment, Causes, Symptoms, Diagnosi

experience in Hunter syndrome; the aim is to provide clini-cians in Latin America with the most current information on the clinical aspects, diagnosis, and management of Hunter syndrome, a serious and progressive disease for which specific treatment is available. This review is aimed at general practitioners and other specialists to promot Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study. Nathalie Guffon 1, Bénédicte Heron 2, Brigitte Chabrol 3, François Feillet 4, Vincent Montauban 5,7 & Vassili Valayannopoulos Mucopolysaccharidosis II, also known as Hunter syndrome, is a rare, X-linked disorder caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase, which catalyzes a step in the catabolism of glycosaminoglycans. In patients with mucopolysaccharidosis II, glycosaminoglycans accumulate within tissues and organs, contributing to the signs and symptoms of the disease HS-FOCUS was developed as disease-specific measure of the impact of Hunter syndrome on HRQL. The HS-FOCUS is designed to gather information on the participant's daily life and wellbeing, satisfaction with treatment, and hospitalizations, as well as on how Hunter syndrome impacts participant's general quality of life

Why Vietnam War Vets Were Treated Poorly When They

Hunter Syndrome (MPSII): Symptoms, Treatment, Diagnosis

In Hunter syndrome, GAGs build up in cells throughout the body due to a deficiency or absence of the enzyme iduronate-2-sulfatase (I2S). This buildup interferes with the way certain cells and organs in the body function and leads to a number of serious symptoms.As the buildup of GAGs continues throughout the cells of the body, signs of Hunter syndrome become more visible Most cases of serotonin syndrome are mild and may be treated by withdrawal of the offending agent and supportive care. Benzodiazepines may be used Hunter Serotonin Toxicity Criteria or. The global Hunter syndrome treatment market can be segmented by treatment type as Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT) and others and by end-users - hospitals, clinics, specialty care unit and others Ramsay Hunt syndrome (also termed Hunt's Syndrome and herpes zoster oticus) is a herpes zoster virus infection of the geniculate ganglion of the facial nerve.; It is caused by reactivation of herpes zoster virus that has previously caused chickenpox in the patient.; Ramsay Hunt syndrome results in paralysis of the facial muscles on the same side of the face as the infection Profile of idursulfase for the treatment of Hunter syndrome Simona Sestito, Ferdinando Ceravolo, Michele Grisolia, Elisa Pascale, Licia Pensabene, Daniela Concolino Department of Pediatrics, University Magna Graecia of Catanzaro, Catanzaro, Italy Abstract: Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is a rare X-linked lysosomal storage disorder caused by deficiency of the enzyme.

Hunter Syndrome (MPS II): Causes, Symptoms, and Treatmen

Neck pain or an injury can leave you feeling dizzy. This condition, known as bow hunter's syndrome or rotational vertebral artery syndrome, makes you feel faint or dizzy when you turn your head Hunter syndrome appears in kids as young as 18 months. It mostly occurs in boys, but very infrequently it's been observed in girls. There is no treatment for Hunter syndrome. Treatment of Hunter syndrome entails management of complications and symptoms. Signs and symptoms of Hunter Syndrome How Is Zellweger Syndrome Diagnosed? Diagnosis of Zellweger typically begins a few hours after birth once the first signs are noticed (typically the distinctive facial features). Blood or urine tests are administered to confirm the diagnosis. Genetic testing can also be done to test for any of the twelve mutations. Is There a Treatment We are encouraged by these new phase 1/2 data, which continue to support the overall safety profile and biomarker effects of DNL310 as an investigational treatment in Hunter syndrome, said.

Hunter Syndrome Treatments - News-Medical

Hunter Syndrome Treatment Market is anticipated to reach USD XX.X MN by 2027, this market report provides the key players, growth, share & forecast of the market based on in-depth research by industry experts. The global market size, trends, along with factors in the hunter syndrome treatment market repor Introduction: Bow hunter's syndrome is a unique clinical entity caused by mechanical occlusion of the vertebral artery on head rotation. Although it is usually treated by direct surgical intervention, we report successful treatment using endovascular stent placement for contralateral vertebral artery stenosis

Causes, Symptom, and Treatment of Bubonic Plague

This is an observational, Pre-phase 1 study of biomarkers in patients with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. Details This is a 2-part, prospective, multicenter, observational study of patients with MPS II to characterize disease-related biomarkers in urine, blood and cerebrospinal fluid (CSF) Hunter's syndrome, also called Mucopolysaccharidosis Ii, rare sex-linked hereditary disorder that varies widely in its severity but is generally characterized by some degree of dwarfism, mental retardation, and deafness.The disease affects only males and makes its first appearance during the first three years of life. Many patients die before age 20 Hunter syndrome, which affects an estimated 7,800 individuals worldwide (according to JCR research), gives rise to a wide range of somatic and neurological symptoms. The current standard of care. About Hunter Syndrome. Hunter syndrome is a severely debilitating rare disease that affects 1 in 162,000 total live births, and mainly males. Hunter syndrome is an X-linked disorder caused by a deficiency or absence of the lysosomal enzyme iduronate-2-sulfatase (I2S), which leads to severe clinical complications and early mortality The largest retrospective Ramsay Hunt syndrome treatment study26 showed a statistically significant improvement in patients treated with prednisone and acyclovir within 3 days of onset. Eighty patients were separated into groups based on the time treatment was started—that is, less than 3 days, 3-7 days, and after 7 days